29

2023

-

11

“China Medical Device Industry Development Report (2023): Current Status and Development Trends of China’s Orthopedic Implant Industry”


Overview of China's Orthopedic Medical Device Industry in 2022

(1) Industry Overview

In recent years, driven by factors such as the accelerating aging population[2] and the pandemic, the scale of medical resource allocation and healthcare service demand has significantly increased. The state has been steadily increasing its investment in health care year after year and continuously improving regulatory standards for the orthopedic implant industry.

In May 2022, the General Office of the State Council issued the “Key Tasks for Deepening the Reform of the Medical and Healthcare System in 2022” [3], which identified the implementation of centralized bulk procurement of pharmaceuticals and medical consumables, the advancement of healthcare service price reforms, and the promotion of reforms in medical insurance payment methods as key tasks for 2022. Under the influence of these multiple reform policies, several national ministries and commissions have focused on the orthopedics medical sector, conducting rigorous oversight and carrying out targeted adjustments and reforms to address the imbalance between patient demand and the availability of medical resources.

(2) Segmented Market Conditions

In 2022, the National Medical Products Administration (NMPA) approved a total of 356 Class III registration certificates, of which 329 were for domestically produced devices and 27 were for imported devices. According to the data, there were 105 trauma products, including 103 domestically produced and 2 imported; 76 joint products, with 64 domestically produced and 12 imported; 99 spinal products, of which 94 were domestically produced and 5 were imported; and 76 sports medicine products, with 68 domestically produced and 8 imported. In 2022, domestically produced Class III registration certificates accounted for 92.4% of the total approvals, highlighting the clear late-mover advantage enjoyed by domestic enterprises in China’s orthopedic sector. With advancements in science and technology, Chinese companies are not only steadily obtaining approvals for conventional products but also intensifying their efforts to develop innovative medical devices. In 2022, the NMPA approved a total of 55 innovative medical device products for market launch, among which 9 were orthopedic-related innovative devices—including implantable spinal cord nerve stimulation systems and surgical navigation and positioning systems[4]. The approval rate for innovative devices has been on an upward trend.

In 2022, affected by the COVID-19 pandemic and following the implementation of centralized bulk procurement of artificial joints organized by the national government as well as bulk procurement of trauma-related implants by Henan Province and two alliances covering Beijing-Tianjin-Hebei, China's orthopedic implant market reached 32 billion yuan, representing a year-on-year growth rate of -6% compared to 2021 (see Table 1). The trauma and joint implant markets are expected to bottom out and rebound by the end of 2023.

Among imported brands, the decline in end-user prices during centralized procurement has been relatively significant, further squeezing product margins and diminishing channel advantages. Meanwhile, leading domestic enterprises are increasingly leveraging their scale advantages in areas such as product R&D, manufacturing, channel promotion, and warehousing and distribution. As a result, the market share of these leading domestic enterprises is expected to rise, and industry concentration in the orthopedic implant sector will continue to increase.

1. Trauma

Affected by pandemic lockdowns, the incidence of trauma-related injuries has declined. Moreover, against the backdrop of volume-based procurement for trauma implants in Henan Province and the two alliances—Beijing-Tianjin-Hebei—trauma implant prices have dropped significantly, leading to a decline in overall market sales. In 2022, among domestic trauma market sales, imports accounted for 1 billion yuan, representing approximately 14% of the total and experiencing a year-on-year decline of 60%; domestically produced products accounted for 86% of sales, with a year-on-year growth rate of -16%.

2. Joint

In September 2021, the National Joint Procurement Office for High-Value Medical Consumables launched a centralized bulk procurement initiative for artificial joints. Through competitive bidding among joint-prosthesis manufacturers, the average price of joint products dropped by as much as 82%. In 2022, with the implementation of the centralized bulk procurement for artificial joints, sales of imported joint products accounted for 42% of the domestic joint market, representing a decline of 33%; meanwhile, the share of domestically produced joint products rose to 58.4%, with a growth rate of -2%.

3. Spine

In 2022, as the COVID-19 situation continued to improve and digital orthopedic technologies—such as percutaneous minimally invasive spinal techniques, interforaminal endoscopic fusion, 3D printing technology, and robot-assisted surgery—were increasingly adopted and promoted, the market size of China's spinal implant industry continued to expand. Sales of imported spinal products accounted for 40% of the domestic spinal market, with a growth rate of 7%; sales of domestically produced spinal products reached 5.2 billion yuan, accounting for 60% of the market and achieving a growth rate of 22%.

The results of the 2022 national centralized bulk procurement of orthopedic and spinal medical consumables have been announced. It is expected that nationwide implementation of this centralized procurement will gradually take place in 2023. Domestic and imported spinal implant companies will face challenges as they adapt to a low-profit business model.

4. Sports Medicine

Sports medicine implants are clinically used primarily in various arthroscopic and open surgical procedures to treat conditions such as ligament, meniscus, and cartilage injuries. With the rapid growth of China’s sports population, an increasingly aging society, and continuously rising medical consumption demands among residents, the sports medicine market is currently undergoing rapid development. Although China’s sports medicine market is still relatively small, it boasts tremendous growth potential, with most of the market share held by imported companies. In 2022, imported sports medicine products accounted for 80% of China’s sales, with a growth rate of 18%, while domestically produced devices accounted for 20% of sales, achieving a growth rate of 100%.

In the past two years, approximately 90% of the registered medical device certificates approved by the NMPA for sports medicine applications have been issued to domestic manufacturers. Several Chinese medical device companies have established relatively comprehensive business footprints in the field of sports medicine, offering more cost-effective and diverse product solutions for the treatment of sports-related injuries.

(3) International Trade

According to the research and analysis conducted on the online query platform for customs statistics provided by the General Administration of Customs of the People’s Republic of China [5], in 2022, China’s total exports of orthopedic implants amounted to approximately US$863 million, representing a year-on-year increase of 21%. Among these, the sub-market of trauma/spine implants recorded exports of about US$755 million, up 17% from the previous year; while artificial joint implants exported approximately US$294 million, marking a year-on-year increase of 35% (see Table 2).

Against the backdrop of successive centralized procurement initiatives in trauma, joint, and spinal care sectors, domestic brands are not only accelerating import substitution but also continuously expanding into overseas markets to seek new growth opportunities. With the full implementation of the EU’s CE certification requirements—from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR)—the requirements for clinical trials alone have significantly increased the difficulty for Chinese orthopedic device companies seeking CE certification, thereby lengthening the certification process and raising certification costs. This situation clashes with the urgent need for these companies to expand into overseas markets, especially given the context of China’s national centralized procurement of orthopedic products.